CeriBell (CBLL) Stock Price, News & Analysis

Company Overview

Ceribell, Inc. (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data. Its Ceribell Clarity algorithm is designed to help clinicians identify potential seizures and status epilepticus in real time, supporting faster clinical evaluation and treatment decisions.

Ceribell’s technology is used by hospitals and healthcare professionals, primarily in the United States, and is intended to complement rather than replace neurologist interpretation and broader neurological assessment. The company was established to address delays and logistical challenges associated with traditional EEG services and has received regulatory clearances for its EEG and seizure-detection products.

Key Stats

• Today's Range: $24.33 to $25.31
• 50-Day Range: $16.28 to $25.04
• 52-Week Range: $10.85 to $25.63
• Volume: 931,884 shs
• Average Volume: 303,646 shs
• Market Capitalization: $935.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.40
• Consensus Rating: Moderate Buy

CeriBell Stock Analysis - MarketRank™

CeriBell scored higher than 38% of companies evaluated by MarketBeat, and ranked 736th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for CeriBell is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

CeriBell has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CeriBell are expected to grow in the coming year, from ($1.96) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CeriBell is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CeriBell is -13.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CeriBell has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.04% of the float of CeriBell has been sold short.

Short Interest Ratio / Days to Cover

CeriBell has a short interest ratio ("days to cover") of 5.58.

Change versus previous month

Short interest in CeriBell has recently decreased by 9.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CeriBell does not currently pay a dividend.

Dividend Growth

CeriBell does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.56

News Sentiment

CeriBell has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for CeriBell this week, compared to 5 articles on an average week.

MarketBeat Follows

2 people have added CeriBell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,085,381.00 in company stock.

Percentage Held by Insiders

17.70% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CeriBell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CBLL
• Previous Symbol: NASDAQ:CBLL
• CIK: 1861107
• Web: www.ceribell.com
• Phone: (800) 436-0826
• Fax: N/A
• Employees: 300
• Year Founded: 2014

Price Target and Rating

• Average Price Target for CeriBell: $24.40
• High Price Target: $30.00
• Low Price Target: $17.00
• Potential Upside/Downside: +0.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.41 million
• Net Margins: -64.73%
• Pretax Margin: -64.73%
• Return on Equity: -44.85%
• Return on Assets: -35.69%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 9.18
• Quick Ratio: 8.79

Sales & Book Value

• Annual Sales: $89.06 million
• Price / Sales: 10.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 5.82

Miscellaneous

• Outstanding Shares: 38,380,000
• Free Float: 31,585,000
• Market Cap: $935.32 million
• Optionable: N/A
• Beta: 0.95